Multiple Myeloma

MAIA Trial: DRd vs Rd in Transplant-Ineligible Patients with MM

Experts on multiple myeloma discuss how to select treatment options in later lines of therapy.

Al-Ola Abdallah, MD;Leyla O. Shune, MD;Nausheen Ahmed, MD;Jordan Snyder, PharmD

Patient Profile 2: A 79-Year-Old with Multiple Myeloma

Leyla O. Shune, MD, reviews the MAIA trial, which looked at DRd vs Rd in patients with transplant-ineligible multiple myeloma.

Al-Ola Abdallah, MD;Leyla O. Shune, MD;Nausheen Ahmed, MD;Jordan Snyder, PharmD

Role of CAR T-cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

The expert panel presents the case of a patient with multiple myeloma and discusses evaluating transplant eligibility in patients with MM.

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Ernest C. Quintin, MD;Thomas Atkinson, MD

Unmet Needs and Future Perspectives in Multiple Myeloma

Before closing out their module on relapsed/refractory multiple myeloma, key opinion leaders reflect on the role of CAR T-cell therapy and patient access to care.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

Relapsed/Refractory Multiple Myeloma: Managing Patients on Bispecific Therapy

A panel of experts discuss unmet needs in multiple myeloma and offer perspectives on the future treatment landscape.

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Ernest C. Quintin, MD;Thomas Atkinson, MD

Bispecific Antibodies vs CAR T-Cell Therapy in Multiple Myeloma

Centering discussion on bispecific therapy, panelists consider dosing strategies and adverse event management in relapsed/refractory multiple myeloma.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

Relapsed/Refractory MM: Safety and Efficacy Data From MonumenTAL-1

An expert panel compares bispecific antibodies with CAR T-cell therapy and discusses treatment sequencing.

Ajai Chari, MD;Carolina D. Schinke, MD

July 6th 2023

Focused discussion on the safety and efficacy data from MonumenTAL-1, which utilized talquetamab monotherapy in patients with relapsed/refractory multiple myeloma.

MonumenTAL-1 in Relapsed/Refractory MM: Overview of Study Design

Ajai Chari, MD;Carolina D. Schinke, MD

July 6th 2023

Following a brief review of the relapsed/refractory multiple myeloma treatment landscape, Carolina Schinke, MD, provides an overview of the MonumenTAL-1 study design.

Key Takeaways from Health Care Systems on the Role of Bispecifics in MM

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

July 5th 2023

The panel closes their discussion by highlighting crucial takeaways about the use of bispecific antibodies in the treatment of multiple myeloma.

Future Perspectives on the Role of Bispecifics in MM

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

July 5th 2023

Doctors discuss the potential of bispecific therapies being used in earlier lines of treatment for multiple myeloma, and the need for understanding and reducing toxicities as much as possible.

Closing Thoughts on Bispecific Antibodies and the Future of R/R MM Treatment

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

July 5th 2023

The panel looks to the future of relapsed/refractory multiple myeloma treatment and the remaining unmet needs for patients.

The standard of care for high-risk multiple myeloma remains unsettled, according to an expert panel from Kansas City.

Experts Spotlight Some of The ‘Biggest Concerns’ In Multiple Myeloma

Al-Ola Abdallah, MD;Nausheen Ahmed, MD;Leyla O. Shune, MD;Jordan Snyder, PharmD

Bispecifics in MM: Future Directions in Care

The standard of care for high-risk multiple myeloma remains unsettled, according to an expert panel from Kansas City.

Rafael Fonseca, MD;Shaji Kumar, MD, Mayo Clinic;Joselle Cook, MBBS, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic

Long-Term Monitoring for CRS and AEs With Bispecific Therapy

Closing out their panel on bispecifics in relapsed/refractory multiple myeloma, key opinion leaders share closing thoughts and hopes for the future treatment landscape.

Cesar Rodriguez, MD;Scott A. Soefje, PharmD;Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC;Frances A. Bell, NP

Selecting Patients for BCMA and Non-BCMA Bispecifics in Multiple Myeloma

Long-term considerations for the detection and treatment of CRS and other adverse events when managing patients with multiple myeloma.

Rafael Fonseca, MD;Shaji Kumar, MD, Mayo Clinic;Joselle Cook, MBBS, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic

Initial Monitoring for CRS and AEs in Patients With MM on Bispecifics

Expert panelists from Mayo Clinic discuss their approach for the use of BCMA and non-BCMA targeting bispecifics, respectively, in patients with relapsed/refractory multiple myeloma.

Cesar Rodriguez, MD;Scott A. Soefje, PharmD;Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC;Frances A. Bell, NP

Updated Results of the MonumenTAL-1 Study in R/R MM

Expert perspectives on ensuring the early detection and treatment of CRS and other adverse events when initiating bispecific therapy in patients with multiple myeloma.

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

July 3rd 2023

Noffar Bar, MD, details data on talquetamab in R/R MM treatment from the MonumenTAL-1 study, and Syed S. Ali, MD, speaks to his experience with teclistamab in clinical practice.

Available Treatment Options for Patients With R/R MM

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

July 3rd 2023

Elan Gorshein, DO, JD, MPH, explains his choice of frontline therapy for patients with relapsed/refractory multiple myeloma.

Optimizing Treatment Strategies in Relapsed/Refractory Multiple Myeloma

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Ernest C. Quintin, MD;Thomas Atkinson, MD

Frontline Treatment Regimens in the Setting of Transplant-Ineligible NDMM

A panel of experts shares insight on treatment sequencing and selection in the setting of relapsed/refractory multiple myeloma.

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Ernest C. Quintin, MD;Thomas Atkinson, MD

MM: Managing Adverse Effects from Bispecific Antibodies

Experts from Ochsner Health highlight treatment options for patients who present with transplant-ineligible newly diagnosed multiple myeloma.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

Maintenance Therapy Considerations for Standard- and High-Risk MM

Experts on multiple myeloma discuss the management of adverse effects from bispecific antibodies.

Al-Ola Abdallah, MD;Leyla O. Shune, MD;Nausheen Ahmed, MD;Jordan Snyder, PharmD

Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma

Experts on multiple myeloma offer clinical insights on treatment options and considerations for patients with standard- and high-risk multiple myeloma.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

Measuring Treatment Response Following Induction Therapy in Patients with MM

An expert panel discusses bispecific antibodies and their mechanisms of action in the treatment of relapsed/refractory multiple myeloma.

Al-Ola Abdallah, MD;Leyla O. Shune, MD;Nausheen Ahmed, MD;Jordan Snyder, PharmD